Sanctuary Advisors LLC Purchases New Position in West Pharmaceutical Services, Inc. $WST

Sanctuary Advisors LLC purchased a new position in West Pharmaceutical Services, Inc. (NYSE:WST) in the second quarter, Holdings Channel reports. The fund purchased 4,155 shares of the medical instruments supplier’s stock, valued at approximately $1,492,000.

Other hedge funds also recently bought and sold shares of the company. Wealth Alliance LLC raised its stake in shares of West Pharmaceutical Services by 3.8% during the 1st quarter. Wealth Alliance LLC now owns 945 shares of the medical instruments supplier’s stock worth $237,000 after buying an additional 35 shares during the period. IFM Investors Pty Ltd increased its holdings in West Pharmaceutical Services by 0.3% in the 1st quarter. IFM Investors Pty Ltd now owns 13,773 shares of the medical instruments supplier’s stock worth $3,452,000 after acquiring an additional 43 shares in the last quarter. Compound Planning Inc. raised its position in West Pharmaceutical Services by 3.6% during the first quarter. Compound Planning Inc. now owns 1,224 shares of the medical instruments supplier’s stock worth $307,000 after acquiring an additional 43 shares during the period. Aptus Capital Advisors LLC lifted its holdings in West Pharmaceutical Services by 5.5% during the fourth quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock valued at $249,000 after purchasing an additional 47 shares in the last quarter. Finally, Cornerstone Planning Group LLC lifted its holdings in West Pharmaceutical Services by 90.9% during the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 50 shares in the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Price Performance

WST stock opened at $350.68 on Thursday. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $386.00. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. The firm has a market capitalization of $24.68 billion, a PE ratio of 44.90, a price-to-earnings-growth ratio of 2.44 and a beta of 1.15. The business has a 50 day simple moving average of $349.99 and a 200-day simple moving average of $302.68.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. The firm had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The firm’s revenue was up 13.8% compared to the same quarter last year. During the same quarter last year, the business posted $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Equities research analysts anticipate that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s payout ratio is currently 11.27%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on WST. Evercore restated an “outperform” rating and set a $425.00 price target on shares of West Pharmaceutical Services in a research report on Monday, July 27th. KeyCorp raised their price objective on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a report on Thursday, July 2nd. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 7th. Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $310.00 to $400.00 in a report on Tuesday, June 9th. Finally, TD Cowen reiterated a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, West Pharmaceutical Services has an average rating of “Moderate Buy” and an average target price of $368.08.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.